Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Macomics, a UK-based cancer immune therapy spinout of University of Edinburgh, has formally launched with $4m of seed funding led by Epidarex Capital with support from Scottish Investment Bank, a subsidiary of government-owned economic development agency Scottish Enterprise. Proceeds from the round will help identify immuno-oncological leads based on the concepts of Jeffrey Pollard, professor and director of the MRC Centre for Reproductive Health at University of Edinburgh, and Luca Cassetta, a principal investigator in the same department. Macomics’ platform aims to circumvent tumour-driven suppression of the immune system by reaching target proteins that are expressed in greater numbers within tumour-associated macrophages compared with normal cells.
Shuuumatu-Worker, a Japan-based moonlighting job matching, has raised a ¥400m ($3.7m) pre-series B round from Tokyo University of Science Innovation Capital and VC firm Energy and Environment Investment. Shuuumatu-Worker raised an undisclosed sum of funding from recruitment services provider En-Japan and VC firm…
